Should analysts change their consensus on Neogen (USA Stocks:NEOG) after the latest surge?
 | By Ellen Johnson | Macroaxis Story |
Neogen is scheduled to announce its earnings tomorrow. As many millenniums are getting excited about health care equipment & supplies space, it is only fair to digest the feasibility of shorting Neogen. We will analyze why Neogen investors may still consider a stake in the business given the latest economic outlook.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Raphi Shpitalnik
On a scale of 0 to 100, Neogen holds a performance score of 7. The company secures a Beta (Market Risk) of 1.7286, which conveys a somewhat significant risk relative to the market. Let's try to break down what Neogen's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neogen will likely underperform. Although it is vital to follow Neogen price patterns, it is good to be conservative about what you can do with the information regarding equity historical price patterns. The philosophy towards estimating future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By analyzing Neogen technical indicators, you can presently evaluate if the expected return of 0.31% will be sustainable into the future. Please exercises Neogen treynor ratio, as well as the relationship between the downside variance and kurtosis to make a quick decision on whether Neogen current price movements will revert.
What is the right price you would pay to acquire a share of Neogen? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.
What is happening with Neogen this year
Annual and quarterly reports issued by Neogen are formal financial statements that are published yearly and quarterly and sent to Neogen stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Neogen often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Neogen. Please refer to our Terms of Use for any information regarding our disclosure principles.